{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-007858","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.858075+00:00","generated_at":"2026-06-27T03:05:42.444113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"PMV Pharma reports FY2021 net loss of $57.8M; cash at $314.1M; PC14586 data expected H1 2022","bullets":["Net loss $57.8M in FY2021 vs $34.4M in FY2020; R&D expenses $36.5M; G&A $21.8M.","Cash, cash equivalents and marketable securities $314.1M as of Dec 31, 2021 vs $361.4M Dec 31, 2020; net cash used in operations $46.6M.","Lead candidate PC14586 Phase 1/2 trial ongoing; initial Phase 1 data expected in first half of 2022.","Advanced WIP1 inhibitor program into lead optimization; appointed Kirsten Flowers to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-007858","json":"https://secwatch.observer/filing/0001564590-22-007858.json","markdown":"https://secwatch.observer/filing/0001564590-22-007858.md","text":"https://secwatch.observer/filing/0001564590-22-007858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000156459022007858/0001564590-22-007858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000156459022007858/pmvp-8k_20220301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:05:42.444113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}